Translate 
Abstract
Abstract Reduction mammoplasty (RM) decreases breast size but may lead to complications such as hematoma. Local tranexamic acid (TXA) is applied during surgery to minimize bleeding during or after the procedure. This systematic review, conducted in August 2024 using PubMed, Ovid Medline, and Ovid Embase, assessed the impact of local TXA on RM. The Methodological Index for Nonrandomized Studies (MINORS) and the Revised Cochrane Risk of Bias (RoB2) tools were employed to assess the risk of bias. Data analysis was performed using RevMan software. In our meta-analysis of five studies involving 608 patients (1216 breasts) undergoing RM, 46.8% of breasts were treated with TXA. Local TXA significantly reduced the 24-hour drain output (mean difference (MD) -11.49, 95% CI [-15.71, -7.26], P < 0.00001). Higher TXA concentrations (20 and 25 mg/mL) significantly reduced hematoma rates (odds ratio (OR) 0.09, 95% CI [0.03, 0.30]; P < 0.0001), while lower concentrations showed no similar effect. TXA also reduced the complication rates in RM (OR 0.63, 95% CI [0.50, 0.80], P = 0.0002), though its impact on drain utilization, duration, and seroma rates were not statistically significant. Local TXA showed promising results, as it reduced the 24-hour drain output, overall occurrence of postoperative complications, and when used in higher concentrations, decreased the hematoma formation. However, we need further Randomized Controlled Trials to confirm the efficacy of different concentrations of TXA in RM.
Published Version
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
